NCT07587710Not yet recruitingPhase 1
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 8 May 2026
- Start date
- 13 May 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07587710
- EudraCT number
- 2025-521647-20
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 35
- From 13 May 2026 to the primary completion date, 1 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known or suspected hypersensitivity to study intervention(s) or related products.
Other
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
Who the study is looking for
- Male or female (sex at birth).
- Age 18-80 years (both inclusive) at the time of signing informed consent.
- Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Summit Clinical Research s.r.o Coordinator of this site? Confirm its status | Bratislava | Slovakia | Unknown status |
| Summit Clinical Research s.r.o. Coordinator of this site? Confirm its status | Malacky | Slovakia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.